drugset
drugset / Trial / NCT03844815

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

NCT03844815 ↗

Phase 1 Active not recruiting 26 enrolled University of Chicago AbbVie · collab
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to learn about the safety and tolerability of an experimental drug, Venetoclax, when it is given along with Decitabine in subjects diagnosed with acute myeloid leukemia (AML).

Timeline

Start
2019-11-18
Primary completion
2027-12-10
Completion
2027-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Venetoclax Small molecule 100 mg Oral
Subject Venetoclax Small molecule 400 mg Oral
Background Decitabine Small molecule 20 mg Intravenous

Indications

acute myeloid leukemia